Testosterone Enanthate Pediatric (Under 12) Dosing: Clinical Guide
Testosterone enanthate is an injectable testosterone ester (brand name Delatestryl, also available as generic testosterone enanthate injection, USP), dissolved in sesame oil and given intramuscularly. It belongs to the same class as testosterone cypionate, another long-acting ester used for hypogonadism replacement. In children under 12, it is used only in a narrow set of circumstances, and this article covers what is established, what specialists commonly do in practice, and where the evidence runs out.
This article is a clinical education reference, not an individualized dosing guide. Any decision to start, adjust, or stop testosterone enanthate in a child under 12 belongs to a pediatric endocrinologist working from that child's own labs, imaging, and growth records.
Direct answer
Testosterone enanthate has no testosterone-specific FDA-approved pediatric dosing schedule for children under 12. The FDA label for testosterone enanthate states that androgen therapy "should be used very cautiously in children and only by specialists who are aware of the adverse effects on bone maturation," without specifying an age floor or a pediatric mg/kg regimen. In practice, pediatric endocrinology centers use low, weight-adjusted starting doses (commonly cited as 25 mg intramuscularly every 4 weeks, or roughly 1 to 2.5 mg/kg per dose) with bone age and growth monitoring, but these numbers come from institutional protocols and case-based practice, not from a randomized controlled trial in this age group. A prescriber and family should treat every specific number in this article as a starting point for discussion with the treating specialist, not a fixed prescription.
Who might actually be a candidate
Children under 12 are rarely candidates for testosterone enanthate. When a pediatric endocrinologist does prescribe it, the indication is almost always one of the following:
- Confirmed primary hypogonadism, for example Klinefelter syndrome (47,XXY), anorchia, or testicular damage from chemotherapy or radiation, with gonadotropin levels elevated in the setting of low testosterone.
- Confirmed secondary (central) hypogonadism, hypothalamic-pituitary disease such as Kallmann syndrome, with low-to-normal gonadotropins alongside low testosterone.
- Selected cases of constitutional delay of growth and puberty (CDGP) with documented psychosocial distress, after non-hormonal options and reassurance have been considered, and only after excluding functional causes of delayed puberty such as chronic illness, undernutrition, or eating disorders.
Diagnosis in all three categories rests on biochemical confirmation (repeated morning testosterone measurement against age-appropriate reference ranges, paired with LH and FSH) rather than on growth curves or physical exam alone. CDGP is the most debated of the three indications in children under 12, and most pediatric endocrinology guidance treats it as a short, time-limited trial rather than ongoing therapy, with reassessment typically built in within months rather than years. The exact duration and dose used for a CDGP trial vary by center; a family should ask the prescribing specialist what published or institutional protocol they are following and why.
What doses are actually used, and how firm is that guidance
There is no single standardized, FDA-specified pediatric dosing table for testosterone enanthate in children under 12. What exists is a mix of manufacturer labeling caution language, adult Endocrine Society guidance that specialists adapt downward, and retrospective/observational pediatric experience. The following table reflects commonly described starting points in pediatric endocrinology practice. Treat it as illustrative of how care is typically sequenced, not as a guideline mandate.
| Phase | Dose (commonly used) | Interval | Typical reassessment |
|---|---|---|---|
| Initiation | ~25 mg IM (or ~1.5 to 2.5 mg/kg) | Every 4 weeks | 3 to 6 months |
| Mid-phase (if tolerated, bone age stable) | ~50 mg IM | Every 4 weeks | 3 to 6 months |
| Transition toward puberty-range dosing | ~75 to 100 mg IM | Every 4 weeks | 6 months |
| Adult replacement range (older adolescent) | ~100 to 200 mg IM | Every 1 to 2 weeks | Ongoing, adult-model follow-up |
A few practical notes that apply regardless of the exact numbers a given center uses:
- Injection site. The vastus lateralis (outer thigh) is generally preferred over the dorsogluteal site in young children because the muscle is more accessible and there is less risk to the sciatic nerve. Needle length and gauge are chosen by the clinical team based on the child's size.
- Concentration and volume. Commercial testosterone enanthate is 200 mg/mL. A 25 mg dose is a very small volume (about 0.125 mL), which requires a precision (tuberculin-style) syringe. Some pediatric centers use a compounded lower-concentration formulation to make the injection volume more practical. Any compounded product should come from an FDA-registered outsourcing facility or a state-licensed pharmacy operating under sterile compounding standards; compounded products do not carry FDA approval for the specific pediatric use and quality can vary by pharmacy.
- Escalation is gated by response, not by calendar. Moving to the next dose tier is conditioned on bone age stability and growth velocity, not simply the passage of a fixed number of months.
Monitoring: what gets tracked and why
Monitoring is not optional in this age group because the two failure modes (under-treatment and over-treatment) both carry lasting consequences: under-treatment leaves hypogonadism unaddressed during a critical window for bone mass accrual and psychosocial development; over-treatment risks premature epiphyseal closure and unwanted virilization.
- Bone age. A hand and wrist X-ray at baseline and roughly every 6 months during treatment is the standard way to watch for accelerated skeletal maturation. Specific numeric thresholds for "too much" bone age advance per 6 months appear in institutional protocols; ask the prescribing endocrinologist what threshold they use and why, since this is not a single FDA- or guideline-mandated number.
- Serum hormones. Trough testosterone (drawn on the day the next injection is due) alongside LH and FSH lets the team check whether the child is being over- or under-replaced and whether the original hypogonadism classification still fits. Pediatric endocrinology practices vary in the exact trough range they target; this should be individualized rather than treated as a universal number.
- Growth velocity and Tanner staging. Height, weight, and pubertal staging at every visit. A meaningful deceleration or an unexpected acceleration in growth velocity, or virilization progressing faster than the intended pubertal timeline, are both reasons to review the dose.
- Complete blood count. Testosterone stimulates red cell production, so a baseline and periodic hematocrit check screens for polycythemia. Adult guidelines generally flag a hematocrit around the mid-50s percent as a reason to reduce or pause dosing; pediatric teams tend to apply a similarly conservative threshold, though this has not been established through a pediatric-specific trial.
- Liver and lipid panels. Testosterone enanthate is an injectable ester, not a 17-alpha-alkylated oral androgen, so it does not carry the same hepatotoxicity signal seen with some oral androgens. Baseline and periodic liver function and lipid testing are still reasonable given testosterone's known effect on HDL cholesterol in some patients.
Safety issues specific to a prepubertal child
Virilization at any dose is possible in a prepubertal child: clitoral or penile enlargement, pubic hair growth, acne, and body odor can all appear. These signs indicate the drug is biologically active, but if they progress faster than the target pubertal timeline, they are also a signal to reduce the dose. Injected testosterone does not carry the transfer risk to household contacts that topical gels do, but sharps disposal and vial handling still need to be taught to caregivers.
Mood and behavior. Exogenous testosterone can plausibly affect mood and behavior in a prepubertal child, but the evidence at low replacement doses in this age group is limited. Families should be told to report significant irritability, aggression, or sleep disruption, since these are generally addressed by adjusting the dose rather than by stopping treatment outright, unless the reaction is severe.
Drug interactions. Testosterone can potentiate oral anticoagulants such as warfarin, so a child on warfarin needs closer INR monitoring around any dose change. Testosterone can also improve insulin sensitivity, so a child with type 1 diabetes may need more frequent glucose monitoring during dose titration.
FDA status, off-label use, and what that means practically
The FDA-approved indication for testosterone enanthate is male hypogonadism, without a specific pediatric dosing regimen or age floor spelled out in the label beyond the caution about bone maturation effects (per the FDA-approved prescribing information for testosterone enanthate). This means most uses in children under 12, including short-course CDGP treatment, are off-label relative to how the drug was studied and labeled, even though the underlying indication (hypogonadism) is on-label in a general sense. Off-label prescribing is common and legal in pediatrics generally, because pediatric-specific trials are frequently not required for initial drug approval. Off-label status does not reduce the prescriber's responsibility to document the clinical rationale, discuss it plainly with the family, and obtain informed consent.
If a compounded formulation is used to make dosing more practical, the pharmacy should be an FDA-registered outsourcing facility or a state-licensed compounding pharmacy operating under sterile compounding standards (per FDA guidance on registered outsourcing facilities). Compounded products are not FDA-approved for this use, and their consistency depends on the compounding pharmacy's own quality controls.
What the evidence does and does not establish
- Established: Testosterone enanthate is FDA-approved for male hypogonadism generally, and its label specifically flags caution in children because of effects on bone maturation. Testosterone is a recognized driver of bone mineral density accrual, and untreated hypogonadism in a growing boy carries real costs to bone health and pubertal development.
- Plausible but not established by controlled pediatric trial data: The specific starting doses, escalation intervals, and monitoring thresholds described above are drawn from specialist consensus, retrospective case series, and institutional protocols rather than a large randomized trial of testosterone enanthate in boys under 12. Claims that short-course CDGP treatment preserves final adult height, or that a particular trough level or bone-age-advance threshold is the correct cutoff, are reasonable clinical extrapolations but have not been confirmed by dedicated pediatric randomized trials.
- Not established / does not transfer: Findings from testosterone trials in adult men, including well-known trials in older men with age-related low testosterone, describe a different population, a different treatment goal (symptom improvement in an already-developed adult), and a different risk profile. They should not be used to justify specific pediatric dosing or monitoring thresholds.
Given that gap, families and prescribers should expect individualized judgment, not a fixed protocol, and should ask explicitly which parts of a proposed treatment plan rest on label language, which rest on adult guideline extrapolation, and which rest on a given center's own experience.
Clinician-family discussion and monitoring framework
This framework is meant to structure the conversation between a family and the prescribing pediatric endocrinologist. It does not replace that conversation, and it does not substitute for the specialist's own protocol.
Before starting: confirm these are settled, not assumed
| Checkpoint | What "confirmed" looks like | If not confirmed |
|---|---|---|
| Diagnosis | Two fasting morning testosterone levels below age-appropriate reference range, plus LH/FSH consistent with primary or secondary hypogonadism, or a documented CDGP work-up excluding functional causes | Do not start; repeat testing or refer for further work-up |
| Bone age baseline | Hand/wrist X-ray on file before first dose | Obtain before dosing, not after |
| Monitoring plan agreed | Family understands the schedule for bone age, trough testosterone, growth velocity, CBC, and lipids | Do not start until logistics (labs, imaging access, follow-up visits) are arranged |
| Off-label status discussed | Family has been told explicitly which part of the plan is off-label and why | Document the conversation before the first injection |
| Exit plan defined | For CDGP: a stated reassessment date and stopping criteria. For permanent hypogonadism: a stated transition plan toward adolescent/adult dosing | Do not proceed without a written plan |
During treatment: escalation vs. stop/hold conditions
| Signal | Reasonable response | Who decides |
|---|---|---|
| Growth velocity or bone age tracking as expected, no excess virilization | Continue current dose, reassess at next scheduled visit | Endocrinologist, per visit schedule |
| Bone age advancing faster than the center's own threshold | Hold dose escalation or reduce dose | Endocrinologist only |
| Growth velocity clearly decelerating without explanation | Pause dosing and investigate | Endocrinologist only |
| Virilization progressing faster than the intended pubertal timeline | Reduce dose; do not simply reassure | Endocrinologist only |
| Hematocrit trending toward the upper range flagged by the treating team | Repeat CBC sooner than scheduled; consider dose reduction | Endocrinologist only |
| Fever above 38.5°C within 24 hours of injection, injection-site abscess, or pain lasting more than 48 hours | Urgent medical contact, same day | Family should not wait for the next scheduled visit |
| New mood, aggression, or sleep changes | Report at next contact; escalate sooner if severe | Family reports; endocrinologist decides on dose change |
Boundary between label guidance and individualized care
The FDA label establishes that androgens require caution and specialist oversight in children; it does not establish a specific pediatric dose, injection interval, or monitoring interval. Everything below that line, starting dose, escalation pace, trough targets, and bone-age thresholds, is the treating pediatric endocrinologist's individualized judgment, informed by institutional experience and the adult Endocrine Society framework adapted downward. A family should feel able to ask, at any point, "is this number from the label, from a guideline written for adults, or from your own practice experience?" A specialist should be able to answer that question directly.
Practical guidance for families
- Storage: Room temperature (68 to 77°F), away from light. Inspect the vial before each use; do not use if the solution is discolored or contains particles.
- Injection technique: The oil-based solution is viscous. Many practices draw the dose up with a larger-gauge needle and switch to a finer needle for injection. Caregivers are typically trained in clinic before administering at home.
- Missed doses: If fewer than 7 days have passed since a missed injection, it is commonly given as soon as possible and the schedule resumed. If more than 7 days have passed, contact the prescribing endocrinologist before giving the dose. Do not double a dose to make up for a missed one.
- Medical alert: A child on testosterone therapy should carry information about the medication, dose, and prescriber, particularly before any surgery or dental procedure involving anesthesia or anticoagulation.
- Annual reconfirmation: The prescriber should confirm in writing, at least yearly, whether continued treatment remains appropriate given the current diagnosis and developmental stage.